idk, traded a little holding IMRN$..lot to like ...
Yea it was nice then. Will be nice again as offering is over $18
If you sold pre-market it sure was. It hit just about $25
Not looking as much a bargain now
$20M shelf offering @ $18.75(ADS)
btw WARRANTS exchange for $10/share, bargain.. IMRN$ IMRNW$ ...
ORAL PILL vaccine LIKE VAXART killer..stay over $20 IMRN$$....
Immuron Ltd. said Tuesday that a component called IMM-124E that is used to manufacture the company's digestive-health supplements showed promise neutralizing the new coronavirus in laboratory tests.
The pre-clinical trials signal that the drug component could be useful in inhibiting the virus in the gastrointestinal tract, Immuron said.
The Melbourne, Australia-based company reported the results of a study in which samples of SARS-CoV-2, the virus that causes Covid-19, were placed in the presence of IMM-124E. Concentrations of IMM-124E between 40 and 160 micrograms per milliliter prevented 90% of viral replication, according to Immuron.
Inhibiting coronavirus in the gastrointestinal tract would be helpful if fecal-oral transmission of SARS-CoV-2 is prevalent, Immuron said. The company said current research on that question is inconclusive.
Immuron typically uses IMM-124E to produce Travelan and Protectyn, over-the-counter digestive supplements.
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
July 21, 2020 07:00 ET | Source: Immuron Limited
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studies
Immuron’s technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the GI Tract
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that IMM-124E used to manufacture the company’s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.
The cytopathic effect inhibition cell-based assay was established and performed by 360 biolabs, a Melbourne based Contract Research Organization using the SARS-CoV-2 hCoV19/Australia/VIC01/2020 virus obtained from Melbourne’s Peter Doherty Institute for Infection and Immunity. The in-vitro assessment of the neutralization of SARS-CoV-2 was performed on four production lots of product used to manufacture Travelan® and Protectyn®. The In-vitro susceptibility of the virus to IMM-124E was determined using the quantitative assay which measures virus replication in the presence of increasing concentrations of the product compared to replication in the absence of the product. The effective concentration of IMM-124E was reported as the concentration of the product at which virus replication is inhibited by 50 percent (EC50) or 90 percent (EC90).
All four production lots produced mean EC50 values of 40.5 to 91.9 ug/mL and inhibited viral replication at concentrations which there was no observed cell toxicity. The concentration of IMM124E at which virus replication was inhibited by 90 percent (EC90) produced mean EC90 values ranging from 48.7 to 155.4 ug/mL for all four lots tested again at concentrations at which there was no observed cell toxicity. A commercially available high protein milk powder product was used as a placebo in the studies and produced EC50 values greater than the observed cellular cytotoxicity concentration of >4800 ug/mL. The control milk powder inhibited viral replication at doses >25,000 ug/mL and more importantly did not inhibit viral replication at doses which it was cytotoxic to cells.
Another major finding made during the study was that cell viability in the presence of IMM-124E was greatly enhanced when compared to placebo. IMM-124E improved cell viability by 180 to 260% relative to controls. These results indicate that IMM-124E at concentrations which inhibited SARSCoV-2 replication improved cell viability.
Bovine coronavirus is widely prevalent in dairy cows and is transmitted by infected feces being taken in via the mouth or nose. The virus initially infects cells in the small intestine, and then spreads through to the colon. The major source of coronavirus is adult cattle carriers shedding the virus in their feces and thereby exposing the newborn calves.
Bovine coronaviruses (BCoVs) cause respiratory and enteric infections in cattle including:
severe diarrhea in newborn calves
winter dysentery in adult cows
bovine infectious respiratory disease (BIRD) in calves and adult cattle
Prophylaxis of BCoV enteric disease in newborn calves is usually obtained by means of vaccination of pregnant cows to enhance the level of maternal antibodies that are transferred to their offspring through colostrum, thus exerting a local protective effect against BCoV-induced enteritis. Specific treatment and prevention of coronavirus also involves the feeding of antibodies against coronavirus. This can be achieved by feeding the antibody rich colostrum from coronavirus vaccinated animals, to calves for the first few weeks of life. Therefore, the possibility of producing a Hyper-immune Bovine Colostrum to severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) is quite high. However, the prevalence and prognosis of digestive system involvement and gastrointestinal symptoms in patients with COVID-19 remains largely unknown.
Colostrum is a complex biological fluid that is rich in nutritional components (vitamins, minerals, and amino acids), immune regulating compounds (immunoglobulins, lactoferrin, cytokines and antimicrobial peptides) and growth factors. The main functions of colostrum are to provide essential nutrients, strengthen the natural defense system, modulate immune response, balance intestinal microbiota, promote tissue growth and maturation of the digestive tract in newborns. Colostrum also has antiviral, antifungal and antibacterial properties which enable it to kill different pathogens like Escherichia coli, rotavirus and Cryptosporidium.
Bovine coronaviruses belong to the family Coronaviridae in the order Nidovirales and are members of subgroup 2a along with swine hemagglutinating encephalomyelitis virus(HEV), canine respiratory CoV, and human CoV-OC43 and HKU1. HEV, which causes wasting disease, is an exception; the others all cause enteric and/or respiratory disease. The severe acute respiratory syndrome (SARS)- CoVs, which are associated with respiratory and enteric infections in humans and animals (eg, civet cats, raccoon dogs, bats), belong to the CoV subgroup 2b.1.
“Armed with the knowledge of Bovine coronavirus enteric disease we were interested in testing IMM-124E against SARS-CoV-2” said Dr Jerry Kanellos, CEO of Immuron Limited.
“We know that SARS-CoV-2 causes an influenza-like disease that is primarily thought to infect the lungs with transmission through the respiratory route ranging from mild respiratory symptoms to severe lung injury, multiorgan failure, and death. Respiratory symptoms have dominated the clinical focus, however gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain are also observed in a growing subset of patients often presenting with no respiratory symptoms. In the United States the Centers for Disease Control and Prevention recently updated the symptoms of coronavirus to include diarrhea. This growing clinical evidence suggests that the Gastrointestinal tract may present another viral target organ. The virus RNA has been detected in anal swabs of patients even after nasopharyngeal testing has turned negative, and cells in the inner-gut lining express high amounts of the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses to gain entry to cells implying the potential for gastrointestinal infection and a fecal–oral transmission route. If fecal–oral transmission is a significant factor in the pandemic then the consequences for an oral therapeutic would be significant, however the research is still inconclusive. The preliminary data set we have generated potentially offers a new oral therapeutic approach to target and directly inhibit the virus in the Gastrointestinal tract and warrants further evaluation to identify the inhibitory substances in our products. The company has filed a provisional patent application in respect of the findings.”
My bad..thought was great company FIRST cure for whatever...
Warrants $4+ behind IMRN share price atm IMRNW$ ...
Wow I may have to buy more...
Told you we had another pop coming.. could run till market close now
4.4M shares trading 40M volume = low floater IMRN$..
This is my favorite stock. It's basically a Cash machine. Goes down with really no volume and then 1 PR skyrockets it. Love it!
One more big pop after 2pm before close
It will but after 2pm or market close IMO
btw warrants exercise for $10..presently $2.50..INRN$ $14...
2M trading float.
Two human phase II clinical trials to be conducted in 2021.
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
6:00 am ET July 20, 2020 (Globe Newswire) Print
-- NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
-- Two human phase II clinical trials to be conducted in 2021
-- One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-- The second trial will focus on ETEC infections
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that the Naval Medical Research Center (NMRC) has received written guidance from the U.S. Food and Drug administration (FDA) in relation to the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.
The Type B meeting with the FDA discussed the Chemistry, Manufacturing and Controls including the proposed release testing specifications of the product as well as the planned clinical studies evaluating the safety and efficacy of the product which the company is developing to prevent Campylobacter and ETEC mediated moderate to severe diarrhea.
The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1. Following FDA review the agency provided a written response to the non-clinical questions posed in the briefing documentation as well as providing additional guidance and comments to support the planned IND submission.
"This is an important milestone in the development of any new drug for therapeutic evaluation. The information obtained from this review will assist in the development of the IND application and provides a clear roadmap forward for conducting the two planned clinical studies next year," said Dr. Jerry Kanellos, CEO of Immuron Ltd. "The company is also please to inform shareholders that the manufacturing program is proceeding as planned. We have completed the second immunisation campaign and are on schedule to harvest the Hyper-immune colostrum in September this year which will be used to manufacture the drug product that will be used to treat moderate to severe campylobacteriosis and ETEC infections."
This release has been authorised by the directors of Immuron Limited.
Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
For more information visit: http://www.immuron.com
Overpay IMRNW$ $2/ea = $12 breakeven..$14 doubles..$16 triples, etc...
Warrants under $2 exercise for $10.. IMRN$ believer/investor ...
I think so..Always money to made as long as it keeps moving the way it has. My average is 2 and change for the half I'm still holding. I'll pick up some more when it settles
I sold all of mine also around 15. But, Bought some more for 10. You think we go back up next week?
I'm suggesting it's not, but was treated like one...
Who said it was..not me. I love this stock. I sold half at $15 pre-market
NOT a pump and dump stock.. low floater IMRN$...